Show simple item record

dc.contributor.authorTolaney, SM
dc.contributor.authorWardley, Andrew M
dc.contributor.authorZambelli, S
dc.contributor.authorHilton, JF
dc.contributor.authorTroso-Sandoval, TA
dc.contributor.authorRicci, F
dc.contributor.authorIm, SA
dc.contributor.authorKim, SB
dc.contributor.authorJohnston, SR
dc.contributor.authorChan, A
dc.contributor.authorGoel, S
dc.contributor.authorCatron, K
dc.contributor.authorChapman, SC
dc.contributor.authorPrice, GL
dc.contributor.authorYang, Z
dc.contributor.authorGainford, MC
dc.contributor.authorAndre, F
dc.date.accessioned2020-06-15T12:57:44Z
dc.date.available2020-06-15T12:57:44Z
dc.date.issued2020en
dc.identifier.citationTolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(6):763-75.en
dc.identifier.pmid32353342en
dc.identifier.doi10.1016/s1470-2045(20)30112-1en
dc.identifier.urihttp://hdl.handle.net/10541/623001
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/ 10.1016/s1470-2045(20)30112-1en
dc.titleAbemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trialen
dc.typeArticleen
dc.contributor.departmentDana-Farber Cancer Institute, Boston, MA, USA.en
dc.identifier.journalLancet Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record